Broadly neutralizing antibodies against HIV-1: Templates for a vaccine

Virology

Volumn 435, Issue 1, 2013, Pages 46-56

  van Gils, Marit J ^a   Sanders, Rogier W ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Broadly neutralizing antibodies; Envelope glycoprotein; HIV 1; Vaccine

Indexed keywords

CD4 ANTIGEN; ERDOSTEINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; ANTIGENICITY; BINDING SITE; CD4+ T LYMPHOCYTE; CONFORMATIONAL TRANSITION; DRUG DESIGN; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN QUATERNARY STRUCTURE; REVIEW;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION, PASSIVE; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY;

HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

EID: 84870701546     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.10.004     Document Type: Review

References (161)

1. Aasa-Chapman M.M., Hayman A., Newton P., Cornforth D., Williams I., Borrow P., Balfe P., McKnight A. Development of the antibody response in acute HIV-1 infection. AIDS 2004, 18:371-381.
2. Azoitei M.L., Correia B.E., Ban Y.E., Carrico C., Kalyuzhniy O., Chen L., Schroeter A., Huang P.S., McLellan J.S., Kwong P.D., Baker D., Strong R.K., Schief W.R. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 2011, 334:373-376.
3. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.-C., Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 2000, 6:200-206.
4. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012, 481:81-84.
5. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
6. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., Ketas T., Yuste E., Desrosiers R.C., Klasse P.J., Maddon P.J., Olson W.C., Moore J.P. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007, 360:329-340.
7. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., Ketas T., Sanders R.W., Maddon P.J., Olson W.C., Moore J.P. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 2005, 79:8812-8827.
8. Berkhout B., Sanders R.W. Gene therapy as a vaccine for HIV-1. Expert Opin. Biol. Ther. 2012, 12:1315-1321.
9. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., Decker J.M., Wycuff D., Harris L., Hawkins N., Wood B., Nathe C., Richman D., Tomaras G.D., Bibollet-Ruche F., Robinson J.E., Morris L., Shaw G.M., Montefiori D.C., Mascola J.R. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 2008, 82:11651-11668.
10. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion- associated structure. J. Virol. 2000, 74:627-643.
11. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
12. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., Fenyo E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 1997, 71:7478-7487.
13. Bonsignori M., Hwang K.K., Chen X., Tsao C.Y., Morris L., Gray E., Marshall D.J., Crump J.A., Kapiga S.H., Sam N.E., Sinangil F., Pancera M., Yongping Y., Zhang B., Zhu J., Kwong P.D., O'Dell S., Mascola J.R., Wu L., Nabel G.J., Phogat S., Seaman M.S., Whitesides J.F., Moody M.A., Kelsoe G., Yang X., Sodroski J., Shaw G.M., Montefiori D., Kepler T.B., Tomaras G.D., Alam S.M., Liao H.X., Haynes B.F. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 2011, 85:9998-10009.
14. Bonsignori M., Pollara J., Moody M.A., Alpert M.D., Chen X., Hwang K.K., Gilbert P.B., Huang Y., Gurley T.C., Kozink D.M., Marshall D.J., Whitesides J.F., Tsao C.Y., Kaewkungwal J., Nitayaphan S., Pitisuttithum P., Rerks-Ngarm S., Kim J.H., Michael N.L., Tomaras G.D., Montefiori D.C., Lewis G.K., DeVico A., Evans D.T., Ferrari G., Liao H.X., Haynes B.F. ADCC-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol 2012.
15. Bontjer I., Land A., Eggink D., Verkade E., Tuin K., Baldwin C., Pollakis G., Paxton W.A., Braakman I., Berkhout B., Sanders R.W. Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J. Virol. 2009, 83:368-383.
16. Bontjer I., Melchers M., Eggink D., David K., Moore J.P., Berkhout B., Sanders R.W. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J. Biol. Chem. 2010, 285:36456-36470.
17. Briney B.S., Willis J.R., Crowe J.E. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS. One 2012, 7:e36750.
18. Bunnik E.M., Euler Z., Welkers M.R., Boeser-Nunnink B.D., Grijsen M.L., Prins J.M., Schuitemaker H. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 2010, 16:995-997.
19. Bunnik E.M., Pisas L., van Nuenen A.C., Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 2008, 82:7932-7941.
20. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W.H., Sawyer L.S.W., Hendry R.M., Dunlop N., Nara P.L., Lamacchia M., Garratty E.M., Stiehm E.R., Bryson Y.J., Cao Y., Moore J.P., Ho D.D., Barbas C.F. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
21. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071.
22. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173.
23. Center R.J., Earl P.L., Lebowitz J., Schuck P., Moss B. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J. Virol. 2000, 74:4448-4455.
24. Chen B., Vogan E.M., Gong H., Skehel J.J., Wiley D.C., Harrison S.C. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433:834-841.
25. Corey L., McElrath M.J. HIV vaccines: mosaic approach to virus diversity. Nat. Med. 2010, 16:268-270.
26. Cortez V., Odem-Davis K., McClelland R.S., Jaoko W., Overbaugh J. HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS. Pathog. 2012, 8:e1002611.
27. Davis K.L., Bibollet-Ruche F., Li H., Decker J.M., Kutsch O., Morris L., Salomon A., Pinter A., Hoxie J.A., Hahn B.H., Kwong P.D., Shaw G.M. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 2009, 83:1240-1259.
28. Decker J.M., Bibollet-Ruche F., Wei X., Wang S., Levy D.N., Wang W., Delaporte E., Peeters M., Derdeyn C.A., Allen S., Hunter E., Saag M.S., Hoxie J.A., Hahn B.H., Kwong P.D., Robinson J.E., Shaw G.M. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 2005, 201:1407-1419.
29. Deeks S.G., Schweighardt B., Wrin T., Galovich J., Hoh R., Sinclair E., Hunt P., McCune J.M., Martin J.N., Petropoulos C.J., Hecht F.M. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 2006, 80:6155-6164.
30. Deng H.K., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Suttons R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of the major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
31. Dey A.K., David K.B., Lu M., Moore J.P. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 2009, 385:275-281.
32. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., Lee F.H., Richman D.D., Doms R.W., Vanham G., Burton D.R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 2007, 81:6548-6562.
33. Doria-Rose N.A., Klein R.M., Manion M.M., O'Dell S., Phogat A., Chakrabarti B., Hallahan C.W., Migueles S.A., Wrammert J., Ahmed R., Nason M., Wyatt R.T., Mascola J.R., Connors M. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 2009, 83:188-199.
34. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., Paxton W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
35. Earl P.L., Sugiura W., Montefiori D.C., Broder C.C., Lee S.A., Wild C., Lifson J., Moss B. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J. Virol. 2001, 75:645-653.
36. Edwards T.G., Hoffman T.L., Baribaud F., Wyss S., LaBranche C.C., Romano J., Adkinson J., Sharron M., Hoxie J.A., Doms R.W. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J. Virol. 2001, 75:5230-5239.
37. Euler Z., Bunnik E.M., Burger J.A., Boeser-Nunnink B.D., Grijsen M.L., Prins J.M., Schuitemaker H. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J. Virol. 2011, 85:7236-7245.
38. Euler Z., van den Kerkhof T.L., van Gils M.J., Burger J.A., Edo-Matas D., Phung P., Wrin T., Schuitemaker H. Longitudinal analysis of early HIV-1 specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J. Virol. 2012, 86:2045-2055.
39. Euler Z., van Gils M.J., Bunnik E.M., Phung P., Schweighardt B., Wrin T., Schuitemaker H. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 2010, 201:1045-1053.
40. Falkowska E., Ramos A., Feng Y., Zhou T., Moquin S., Walker L.M., Wu X., Seaman M.S., Wrin T., Kwong P.D., Wyatt R.T., Mascola J.R., Poignard P., Burton D.R. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 2012, 86:4394-4403.
41. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., Kuiken C., Haynes B., Letvin N.L., Walker B.D., Hahn B.H., Korber B.T. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med 2007, 13:100-106.
42. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191:654-665.
43. Forsell M.N., Schief W.R., Wyatt R.T. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr. Opin. HIV AIDS 2009, 4:380-387.
44. Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 2009, 4:388-393.
45. Frost S.D., Wrin T., Smith D.M., Kosakovsky Pond S.L., Liu Y., Paxinos E., Chappey C., Galovich J., Beauchaine J., Petropoulos C.J., Little S.J., Richman D.D. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Nat. Acad. Sci. U.S.A 2005, 102:18514-18519.
46. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., Korber B. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360.
47. Girard M.P., Osmanov S.K., Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006, 24:4062-4081.
48. Gray E.S., Moore P.L., Choge I.A., Decker J.M., Bibollet-Ruche F., Li H., Leseka N., Treurnicht F., Mlisana K., Shaw G.M., Karim S.S., Williamson C., Morris L. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 2007, 81:6187-6196.
49. Haynes B.F. Maturation pathways of broad neutralizing antibodies: blueprints for vaccine design. AIDS Vaccine 2012, 2012. (Presentation).
50. Haynes B.F., Fleming J., Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
51. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
52. Haynes B.F., Kelsoe G., Harrison S.C., Kepler T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012, 30:423-433.
53. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-W23.
54. Herrera C., Klasse P.J., Michael E., Kake S., Barnes K., Kibler C.W., Campbell-Gardener L., Si Z., Sodroski J., Moore J.P., Beddows S. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 2005, 338:154-172.
55. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W., Marx P.A., Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15:951-954.
56. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433.
57. Hu G., Liu J., Taylor K.A., Roux K.H. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J. Virol. 2011, 85:2741-2750.
58. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., Imamichi H., Bailer R.T., Chakrabarti B., Sharma S.K., Alam S.M., Wang T., Yang Y., Zhang B., Migueles S.A., Wyatt R., Hanyes B.F., Kwong P.D., Mascola J.R., Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, in press.
59. Kang Y.K., Andjelic S., Binley J.M., Crooks E.T., Franti M., Iyer S.P., Donovan G.P., Dey A.K., Zhu P., Roux K.H., Durso R.J., Parsons T.F., Maddon P.J., Moore J.P., Olson W.C. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009, 27:5120-5132.
60. Kim M., Qiao Z.S., Montefiori D.C., Haynes B.F., Reinherz E.L., Liao H.X. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res. Hum. Retroviruses 2005, 21:58-67.
61. Kong W.P., Wu L., Wallstrom T.C., Fischer W., Yang Z.Y., Ko S.Y., Letvin N.L., Haynes B.F., Hahn B.H., Korber B., Nabel G.J. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J. Virol. 2009, 83:2201-2215.
62. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 2001, 58:19-42.
63. Korber B., Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS 2009, 4:408-417.
64. Kovacs J.M., Nkolola J.P., Peng H., Cheung A., Perry J., Miller C.A., Seaman M.S., Barouch D.H., Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Nat. Acad. Sci. U.S.A 2012, 109:12111-12116.
65. Krachmarov C.P., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J. Virol. 2006, 80:7127-7135.
66. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
67. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
68. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.C., Venturi M., Petropoulos C.J., Wrin T., Dimitrov D.S., Robinson J., Kwong P.D., Wyatt R.T., Sodroski J., Burton D.R. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 2003, 77:10557-10565.
69. Land A., Braakman I. Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum. Biochimie 2001, 83:783-790.
70. Lederman M.M., Alter G., Daskalakis D.C., Rodriguez B., Sieg S.F., Hardy G., Cho M., Anthony D., Harding C., Weinberg A., Silverman R.H., Douek D.C., Margolis L., Goldstein D.B., Carrington M., Goedert J.J. Determinants of protection among high risk HIV seronegative persons-an overview. J. Infect. Dis. 2010, 202:S333-S338.
71. Li B., Decker J.M., Johnson R.W., Bibollet-Ruche F., Wei X., Mulenga J., Allen S., Hunter E., Hahn B.H., Shaw G.M., Blackwell J.L., Derdeyn C.A. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 2006, 80:5211-5218.
72. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., Migueles S.A., Wu X., Phogat A., Shaw G.M., Connors M., Hoxie J., Mascola J.R., Wyatt R. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 2009, 83:1045-1059.
73. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
74. Madhi S.A., Adrian P., Kuwanda L., Jassat W., Jones S., Little T., Soininen A., Cutland C., Klugman K.P. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007, 25:2451-2457.
75. Mahalanabis M., Jayaraman P., Miura T., Pereyra F., Chester E.M., Richardson B., Walker B., Haigwood N.L. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J. Virol. 2009, 83:662-672.
76. Malherbe D.C., Doria-Rose N.A., Misher L., Beckett T., Puryear W.B., Schuman J.T., Kraft Z., O'Malley J., Mori M., Srivastava I., Barnett S., Stamatatos L., Haigwood N.L. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 2011, 85:5262-5274.
77. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., Birx D.L. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73:4009-4018.
78. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
79. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
80. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542-554.
81. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., O'Dell S., Patel N., Shahzad-ul-Hussan S., Yang Y., Zhang B., Zhou T., Zhu J., Boyington J.C., Chuang G.Y., Diwanji D., Georgiev I., Kwon Y.D., Lee D., Louder M.K., Moquin S., Schmidt S.D., Yang Z.Y., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Burton D.R., Koff W.C., Walker L.M., Phogat S., Wyatt R., Orwenyo J., Wang L.X., Arthos J., Bewley C.A., Mascola J.R., Nabel G.J., Schief W.R., Ward A.B., Wilson I.A., Kwong P.D. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
82. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 2010, 10:11-23.
83. Melchers M., Bontjer I., Tong T., Chung N.P., Klasse P.J., Eggink D., Montefiori D.C., Gentile M., Cerutti A., Olson W.C., Berkhout B., Binley J.M., Moore J.P., Sanders R.W. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J. Virol. 2012, 86:2488-2500.
84. Melchers M., Matthews K., de Vries R.P., Eggink D., van M.T., Bontjer I., van de Sandt C., David K., Berkhout B., Moore J.P., Sanders R.W. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology 2011, 8:48.
85. Miura T., Brumme C.J., Brockman M.A., Brumme Z.L., Pereyra F., Block B.L., Trocha A., John M., Mallal S., Harrigan P.R., Walker B.D. HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J. Virol. 2009, 83:3407-3412.
86. Montefiori D.C., Karnasuta C., Huang Y., Ahmed H., Gilbert P., de Souza M.S., McLinden R., Tovanabutra S., Laurence-Chenine A., Sanders-Buell E., Moody M.A., Bonsignori M., Ochsenbauer C., Kappes J., Tang H., Greene K., Gao H., LaBranche C.C., Andrews C., Polonis V.R., Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Self S.G., Berman P.W., Francis D., Sinangil F., Lee C., Tartaglia J., Robb M.L., Haynes B.F., Michael N.L., Kim J.H. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 2012, 206:431-441.
87. Moody M.A., Zhang R., Walter E.B., Woods C.W., Ginsburg G.S., McClain M.T., Denny T.N., Chen X., Munshaw S., Marshall D.J., Whitesides J.F., Drinker M.S., Amos J.D., Gurley T.C., Eudailey J.A., Foulger A., DeRosa K.R., Parks R., Meyerhoff R.R., Yu J.S., Kozink D.M., Barefoot B.E., Ramsburg E.A., Khurana S., Golding H., Vandergrift N.A., Alam S.M., Tomaras G.D., Kepler T.B., Kelsoe G., Liao H.X., Haynes B.F. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 2011, 6:e25797.
88. Moore P.L., Gray E.S., Choge I.A., Ranchobe N., Mlisana K., bdool Karim S.S., Williamson C., Morris L. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 2008, 82:1860-1869.
89. Moore P.L., Gray E.S., Sheward D., Madiga M., Ranchobe N., Lai Z., Honnen W.J., Nonyane M., Tumba N., Hermanus T., Sibeko S., Mlisana K., Abdool Karim S.S., Williamson C., Pinter A., Morris L. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 2011, 85:3128-3141.
90. Moore P.L., Ranchobe N., Lambson B.E., Gray E.S., Cave E., Abrahams M.R., Bandawe G., Mlisana K., bdool Karim S.S., Williamson C., Morris L. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009, 5:e1000598.
91. Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M., Ott R.G., Shukair S., Artyomov M.N., Pietzsch J., Connors M., Pereyra F., Walker B.D., Ho D.D., Wilson P.C., Seaman M.S., Eisen H.N., Chakraborty A.K., Hope T.J., Ravetch J.V., Wardemann H., Nussenzweig M.C. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467:591-595.
92. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67:6642-6647.
93. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 2004, 78:10724-10737.
94. Pancera M., Majeed S., Ban Y.E., Chen L., Huang C.C., Kong L., Kwon Y.D., Stuckey J., Zhou T., Robinson J.E., Schief W.R., Sodroski J., Wyatt R., Kwong P.D. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Nat. Acad. Sci. U.S.A 2010, 107:1166-1171.
95. Pancera M., McLellan J.S., Wu X., Zhu J., Changela A., Schmidt S.D., Yang Y., Zhou T., Phogat S., Mascola J.R., Kwong P.D. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 2010, 84:8098-8110.
96. Pancera M., Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 2005, 332:145-156.
97. Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 2004, 10:806-810.
98. Parren P.W.H.I., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75:8240-8347.
99. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., Stanfield R.L., Julien J.P., Ramos A., Crispin M., Depetris R., Katpally U., Marozsan A., Cupo A., Maloveste S., Liu Y., McBride R., Ito Y., Sanders R.W., Ogohara C., Paulson J.C., Feizi T., Scanlan C.N., Wong C.H., Moore J.P., Olson W.C., Ward A.B., Poignard P., Schief W.R., Burton D.R., Wilson I.A. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
100. Pejchal R., Gach J.S., Brunel F.M., Cardoso R.M., Stanfield R.L., Dawson P.E., Burton D.R., Zwick M.B., Wilson I.A. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J. Virol. 2009, 83:8451-8462.
101. Pereyra F., Addo M.M., Kaufmann D.E., Liu Y., Miura T., Rathod A., Baker B., Trocha A., Rosenberg R., Mackey E., Ueda P., Lu Z., Cohen D., Wrin T., Petropoulos C.J., Rosenberg E.S., Walker B.D. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 2008, 197:563-571.
102. Piantadosi A., Panteleeff D., Blish C.A., Baeten J.M., Jaoko W., McClelland R.S., Overbaugh J. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 2009, 83:10269-10274.
103. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., Kayman S.C. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 2004, 78:5205-5215.
104. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., Van Griensven F., Hu D., Tappero J.W., Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194:1661-1671.
105. Powell R.L., Kinge T., Nyambi P.N. Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus. J. Virol. 2010, 84:9415-9426.
106. Prabakaran P., Zhu Z., Chen W., Gong R., Feng Y., Streaker E., Dimitrov D.S. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front. Microbiol. 2012, 3:277.
107. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Nat. Acad. Sci. U.S.A 2003, 100:4144-4149.
108. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012.
109. Rong R., Bibollet-Ruche F., Mulenga J., Allen S., Blackwell J.L., Derdeyn C.A., Decamp A.C., Carrico C., Menis S., Magaret C.A., Ahmed H., Juraska M., Chen L., Konopa P., Nariya S., Stoddard J.N., Wong K., Zhao H., Deng W., Maust B.S., Bose M., Howell S., Bates A., Lazzaro M., O'Sullivan A., Lei E., Bradfield A., Ibitamuno G., Assawadarachai V., O'connell R.J., Desouza M.S., Nitayaphan S., Rerks-Ngarm S., Robb M.L., McLellan J.S., Georgiev I., Kwong P.D., Carlson J.M., Michael N.L., Schief W.R., Gilbert P.B., Mullins J.I., Kim J.H. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 2007, 81:1350-1359.
110. Rong R., Li B., Lynch R.M., Haaland R.E., Murphy M.K., Mulenga J., Allen S.A., Pinter A., Shaw G.M., Hunter E., Robinson J.E., Gnanakaran S., Derdeyn C.A. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 2009, 5:e1000594.
111. Sagar M., Wu X., Lee S., Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 2006, 80:9586-9598.
112. Sanders R.W. Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine. Expert. Rev. Vaccines 2011, 10:1117-1120.
113. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002, 76:7293-7305.
114. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., Theiler J., Szinger J., Balachandran H., Buzby A., Quinn D., Parks R.J., Tsao C.Y., Carville A., Mansfield K.G., Pavlakis G.N., Felber B.K., Haynes B.F., Korber B.T., Letvin N.L. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 2010, 16:324-328.
115. Santra S., Muldoon M., Watson S., Buzby A., Balachandran H., Carlson K.R., Mach L., Kong W.P., McKee K., Yang Z.Y., Rao S.S., Mascola J.R., Nabel G.J., Korber B.T., Letvin N.L. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 2012, 428:121-127.
116. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001, 293:1155-1159.
117. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., Yu X., Wood B., Self S., Kalams S., Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:757-769.
118. Sather D.N., Stamatatos L. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 2010, 28(Suppl 2):B8-12.
119. Scanlan C.N., Pantophlet R., Wormald M.R., Ollman Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., Burton D.R. The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of alfa1->2 Mannose Residues on the Outer Face of gp120. J. Virol. 2002, 76:7306-7321.
120. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., Phogat A., Chakrabarti B., Li Y., Connors M., Pereyra F., Walker B.D., Wardemann H., Ho D., Wyatt R.T., Mascola J.R., Ravetch J.V., Nussenzweig M.C. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
121. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Olivera T.Y., Pietzsch J., Fenyo D., Abadir A., Velinzon K., Hurley A., Myung S., Boulad F., Poignard P., Burton D., Pereyra F., Ho D.D., Walker B.D., Seaman M.S., Bjorkman P.J., Chait B.T., Nussenzweig M.C. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science 2011, 333:1633-1637.
122. Schrödinger,L.L.(2010). The PyMOL Molecular Graphics System, Version 1.3 r1.
123. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., Bhattacharya T., Lapedes A., Polonis V.R., McCutchan F.E., Gilbert P.B., Self S.G., Korber B.T., Montefiori D.C., Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84:1439-1452.
124. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infection of macaque monkeys. Nat. Med. 1999, 5:204-210.
125. Si Z., Phan N., Kiprilov E., Sodroski J. Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res. Hum. Retroviruses 2003, 19:217-226.
126. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., Lehrman J.K., Boaz M., Tarragona-Fiol T., Miiro G., Birungi J., Pozniak A., McPhee D., Manigart O., Karita E., Inwoley A., Jaoko W., Dehovitz J., Bekker L.G., Pitisuttithum P., Paris R., Walker L.M., Poignard P., Wrin T., Fast P.E., Burton D.R., Koff W.C. HIV-1 elite neutralizers: individuals with broad and potent neutralizing activity identified using a high throughput neutralization assay together with an analytical selection algorithm. J. Virol. 2009, 83:7337-7348.
127. Spira S., Wainberg M.A., Loemba H., Turner D., Brenner B.G. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J. Antimicrob. Chemother. 2003, 51:229-240.
128. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 2009, 15:866-870.
129. Starcich B.R., Hahn B.H., Shaw G.M., McNeely P.D., Modrow S., Wolf H., Parks E.S., Parks W.P., Josephs S.F., Gallo R.C. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 1986, 45:637-648.
130. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001, 17:1757-1765.
131. Taylor B.S., Sobieszczyk M.E., McCutchan F.E., Hammer S.M. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 2008, 358:1590-1602.
132. Tomaras G.D., Yates N.L., Liu P., Qin L., Fouda G.G., Chavez L.L., Decamp A.C., Parks R.J., Ashley V.C., Lucas J.T., Cohen M., Eron J., Hicks C.B., Liao H.X., Self S.G., Landucci G., Forthal D.N., Weinhold K.J., Keele B.F., Hahn B.H., Greenberg M.L., Morris L., Karim S.S., Blattner W.A., Montefiori D.C., Shaw G.M., Perelson A.S., Haynes B.F. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008, 82:12449-12463.
133. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., Manrique A., Huber M., Rehr M., Oxenius A., Weber R., Stiegler G., Vcelar B., Katinger H., Aceto L., Gunthard H.F. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 2005, 11:593-594.
134. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas C.F., Burton D.R., Ho D.D., Moore J.P. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 1995, 69:6609-6617.
135. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996, 70:1100-1108.
136. van den Kerkhof T.L.G.M., Euler Z., van Gils M.J., Boeser-Nunnink B.D., Sanders R.W., Schuitemaker H. HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals. Retrovirology 2012, 9(suppl 2). 52(Abstract).
137. van Gils M.J., Bunnik E.M., Boeser-Nunnink B.D., Burger J.A., Terlouw-Klein M., Verwer N., Schuitemaker H. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J. Virol. 2011, 85:6986-6995.
138. van Gils M.J., Euler Z., Schweighardt B., Wrin T., Schuitemaker H. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009, 23:2405-2414.
139. van Montfort T., Melchers M., Isik G., Menis S., Huang P.S., Matthews K., Michael E., Berkhout B., Schief W.R., Moore J.P., Sanders R.W. A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. J. Biol. Chem. 2011, 286:22250-22261.
140. Veit O., Niedrig M., Chapuis-Taillard C., Cavassini M., Mossdorf E., Schmid P., Bae H.G., Litzba N., Staub T., Hatz C., Furrer H. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin. Infect. Dis. 2009, 48:659-666.
141. Wahome N., Pfeiffer T., Ambiel I., Yang Y., Keppler O.T., Bosch V., Burkhard P. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem. Biol. Drug Des. 2012, 80:349-357.
142. Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320:760-764.
143. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 2010, 22:358-366.
144. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.H., Phogat S., Wrin T., Simek M.D., Principal Investigators P.G., Koff W.C., Wilson I.A., Burton D.R., Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
145. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Miiro G., Serwanga J., Pozniak A., McPhee D., Manigart O., Mwananyanda L., Karita E., Inwoley A., Jaoko W., Dehovitz J., Bekker L.G., Pitisuttithum P., Paris R., Allen S., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
146. Walker L.M., Simek M.D., Priddy F., Gach J.S., Wagner D., Zwick M.B., Phogat S.K., Poignard P., Burton D.R. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 2010, 6.
147. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
148. West A.P., Diskin R., Nussenzweig M.C., Bjorkman P.J. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Nat. Acad. Sci. U.S.A 2012, 109:E2083-E2090.
149. Willey R., Nason M.C., Nishimura Y., Follmann D.A., Martin M.A. Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. AIDS Res. Hum. Retroviruses 2010, 26:89-98.
150. Wrammert J., Koutsonanos D., Li G.M., Edupuganti S., Sui J., Morrissey M., McCausland M., Skountzou I., Hornig M., Lipkin W.I., Mehta A., Razavi B., Del R.C., Zheng N.Y., Lee J.H., Huang M., Ali Z., Kaur K., Andrews S., Amara R.R., Wang Y., Das S.R., O'Donnell C.D., Yewdell J.W., Subbarao K., Marasco W.A., Mulligan M.J., Compans R., Ahmed R., Wilson P.C. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011, 208:181-193.
151. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
152. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., O'Dell S., Perfetto S., Schmidt S.D., Shi W., Wu L., Yang Y., Yang Z.Y., Yang Z., Zhang Z., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Simek M., Burton D.R., Koff W.C., Doria-Rose N., Connors M., Mullikin J.C., Nabel G.J., Roederer M., Shapiro L., Kwong P.D., Mascola J.R. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
153. Wu Y., Yang Z.Y., Li Y., Hogerkorp C., Schief W., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N., McKee K., O'Dell S., Louder M.K., Wycuff D., Feng Y., Nason M., Doria-Rose N.A., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope surface identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, In Press.
154. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski J. The antigenic structure of the HIV gp120 envelope protein. Nature 1998, 393:705-711.
155. Xiao X., Chen W., Feng Y., Zhu Z., Prabakaran P., Wang Y., Zhang M.Y., Longo N.S., Dimitrov D.S. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 2009, 390:404-409.
156. Yang X., Wyatt R., Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 2001, 75:1165-1171.
157. Zhang M.Y., Yuan T., Li J., Rosa B.A., Watkins J.D., Guenaga J., Yang Z., Wang Y., Wilson R., Li Y., Polonis V.R., Pincus S.H., Ruprecht R.M., Dimitrov D.S. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS One 2012, 7:e44241.
158. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Do K.Y., Scheid J., Shi W., Xu L., Yang Y., Zhu J., Nussenzweig M.C., Sodroski J., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
159. Zhou T., Xu L., Dey B., Hessell A.J., Van R.D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., Sodroski J., Wyatt R., Nabel G.J., Kwong P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
160. Zolla-Pazner S., Kong X.P., Jiang X., Cardozo T., Nadas A., Cohen S., Totrov M., Seaman M.S., Wang S., Lu S. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J. Virol. 2011, 85:9887-9898.
161. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 2005, 79:1252-1261.